PRESS RELEASE 15 Oct 2021 at 17:55
U.S. FDA Approves Cyltezo® (adalimumab-adbm) as First Interchangeable Biosimilar with Humira®
PRESS RELEASE 14 May 2019 at 08:35
Boehringer Ingelheim announces resolution of Cyltezo® patent litigation
PRESS RELEASE 29 Aug 2017 at 09:13
Boehringer Ingelheim Pharmaceuticals, Inc. receives FDA approval for CyltezoTM (adalimumab-adbm), a biosimilar to Humira®, for the treatment of multiple chronic inflammatory diseases
PRESS RELEASE 27 Jul 2017 at 09:10